[Clinical Observation of Standard IA Regimen As Induction Chemotherapy in 242 Patients with Newly Diagnosed Acute Myeloid Leukemia]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2018 May 21

PMID 29779333

Authors

J Y Huang

W X Liu

Y Lian

H H Zhao

H X Wu

H Lu

L J Chen

G S He

J Y Li

S X Qian

Affiliations

Soon will be listed here.

References

Behl D, Porrata L, Markovic S, Letendre L, Pruthi R, Hook C . Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia. 2005; 20(1):29-34. DOI: 10.1038/sj.leu.2404032. View

Beksac M, Arslan O, Koc H, Akan H, Ilhan O, Arat M . Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia. Med Oncol. 1998; 15(3):183-90. DOI: 10.1007/BF02821937. View

Devillier R, Bertoli S, Prebet T, Huguet F, Etienne A, Charbonnier A . Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. Am J Hematol. 2014; 90(2):E29-30. DOI: 10.1002/ajh.23884. View

Bonnet D, Dick J . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7):730-7. DOI: 10.1038/nm0797-730. View

Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N . Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2010; 117(8):2358-65. DOI: 10.1182/blood-2010-03-273243. View

Bozoglan H, Ergene U, Yoleri L . Use of cytarabine and idarubicin in a newly diagnosed AML patient with a severe wound. Transfus Apher Sci. 2011; 45(1):17-20. DOI: 10.1016/j.transci.2011.06.016. View

Juliusson G, Lazarevic V, Horstedt A, Hagberg O, Hoglund M . Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012; 119(17):3890-9. PMC: 3358248. DOI: 10.1182/blood-2011-12-379008. View

Chen Y, Lin S, Yao M, Chen T, Tsao C, Chen T . Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience. Semin Hematol. 1996; 33(4 Suppl 3):30-4. View

Slovak M, Kopecky K, Cassileth P, Harrington D, Theil K, Mohamed A . Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000; 96(13):4075-83. View

10.

Mandelli F, Vignetti M, Suciu S, Stasi R, Petti M, Meloni G . Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009; 27(32):5397-403. PMC: 2773224. DOI: 10.1200/JCO.2008.20.6490. View

11.

Byrd J, Kitada S, Flinn I, Aron J, Pearson M, Lucas D . The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002; 99(3):1038-43. DOI: 10.1182/blood.v99.3.1038. View

12.

Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S . Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991; 77(8):1666-74. View

13.

Fernandez H, Sun Z, Yao X, Litzow M, Luger S, Paietta E . Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009; 361(13):1249-59. PMC: 4480917. DOI: 10.1056/NEJMoa0904544. View

14.

Luskin M, Lee J, Fernandez H, Abdel-Wahab O, Bennett J, Ketterling R . Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016; 127(12):1551-8. PMC: 4807422. DOI: 10.1182/blood-2015-07-657403. View